<br/ >1. Pregnant or breast feeding, <br/ >2. On specific monoclonal antibodies, or other drug trial treatment for COVID-19 within one week prior to study enrolment, <br/ >3. Liver function tests >2 fold of upper limits of normal (ULN) reference levels of the respective testing assay. <br/ >4. Patients with known hypersensitive to leflunomide <br/ >5. Patients with severe immunodeficiency syndrome and hypoalbuminaemia.

<br/ >1. Pregnant or breast feeding, <br/ >2. On specific monoclonal antibodies, or other drug trial treatment for COVID-19 within one week prior to study enrolment, <br/ >3. Liver function tests >2 fold of upper limits of normal (ULN) reference levels of the respective testing assay. <br/ >4. Patients with known hypersensitive to leflunomide <br/ >5. Patients with severe immunodeficiency syndrome and hypoalbuminaemia.

N/A

N/A

<br/ >1. Pregnant or breast feeding, <br/ >2. On specific monoclonal antibodies, or other drug trial treatment for COVID-19 within one week prior to study enrolment, <br/ >3. Liver function tests >2 fold of upper limits of normal (ULN) reference levels of the respective testing assay. <br/ >4. Patients with known hypersensitive to leflunomide <br/ >5. Patients with severe immunodeficiency syndrome and hypoalbuminaemia.

<br/ >1. Pregnant or breast feeding, <br/ >2. On specific monoclonal antibodies, or other drug trial treatment for COVID-19 within one week prior to study enrolment, <br/ >3. Liver function tests >2 fold of upper limits of normal (ULN) reference levels of the respective testing assay. <br/ >4. Patients with known hypersensitive to leflunomide <br/ >5. Patients with severe immunodeficiency syndrome and hypoalbuminaemia.